Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Spero Therapeutics revenue
Spero Therapeutics's revenue is $48.0 million.
What is Spero Therapeutics's revenue?
- Spero Therapeutics's revenue growth from 2016 to 2024 is 14,221.49%.
- Spero Therapeutics has 41 employees, and the revenue per employee ratio is $1,170,170.
- Spero Therapeutics's peak quarterly revenue was $73.5M in 2023(q4).
- Spero Therapeutics peak revenue was $103.8M in 2023.
- Spero Therapeutics annual revenue for 2023 was 103.8M, 93.95% growth from 2022.
- Spero Therapeutics annual revenue for 2024 was 48.0M, -53.77% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Spero Therapeutics historical revenue
Spero Therapeutics's peak revenue was $103.8M in 2023. The peak quarterly revenue was $73.5M in 2023(q4).
Spero Therapeutics's revenue increased from $335.0k in 2016 to $48.0M currently. That's a 14,221.49% change in annual revenue.
Spero Therapeutics annual revenue
Spero Therapeutics annual revenue over time
| Fiscal year / year | Spero Therapeutics revenue |
|---|---|
| 2016 | $335,000 |
| 2017 | $2.0M |
| 2018 | $4.0M |
| 2019 | $18.1M |
| 2020 | $9.3M |
| 2021 | $18.3M |
| 2022 | $53.5M |
| 2023 | $103.8M |
| 2024 | $48.0M |
How accurately did Spero Therapeutics' revenue projections match actual performance?
Spero Therapeutics annual growth
Spero Therapeutics saw the greatest revenue growth in 2017, when revenue increased by 490.75%.
Spero Therapeutics had the lowest revenue growth in 2020, when revenue changed by -48.59%.
Spero Therapeutics annual growth rate over time
| Year | Spero Therapeutics growth |
|---|---|
| 2017 | 491%↑ |
| 2018 | 100%↑ |
| 2019 | 358%↑ |
| 2020 | -49%↓ |
| 2021 | 96%↑ |
| 2022 | 193%↑ |
| 2023 | 94%↑ |
| 2024 | -54%↓ |
Spero Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Spero Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | $463,000 | - | - |
| 2019 | $3.8M | $2.2M | $4.6M | ($9.8M) |
| 2020 | $1.7M | $1.7M | $4.0M | ($7.2M) |
| 2021 | - | $2.1M | $708,987 | $256,102 |
| 2022 | $246,948 | $894,255 | $1.1M | $47.4M |
| 2023 | $740,662 | $786,182 | $23.4M | $73.5M |
| 2024 | $4.2M | $6.0M | $7.8M | $15.0M |
Spero Therapeutics jobs nearby
Do you work at Spero Therapeutics?
Did Spero Therapeutics meet its revenue projections?
Spero Therapeutics financial information
| CEO | Ankit Mahadevia M.d |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 41 |
| Date Founded | 2013 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 2 |
| Revenue | $48.0M |
| Net Income | -$46,415,000 |
| Tax Rate | -0.0% |
| Total Assets | $124,802,000 |
| Ticker | SPRO |
Spero Therapeutics jobs you might like
Spero Therapeutics financing
Spero Therapeutics received early financing of $3.0M on 2014-04-09.
| Series | Round size | Date |
|---|---|---|
| Series A | $3M | 04/2014 |
| Series A | $30M | 06/2015 |
| Series B | $30M | 02/2016 |
| Series C | $51.7M | 03/2017 |
| Grant | $6.8M | 03/2017 |
| Grant | $54M | 07/2018 |
| Post Ipo Equity | $75M | 07/2018 |
| Grant | $5.9M | 07/2019 |
| Post Ipo Equity | $40M | 06/2021 |
| Post Ipo Debt | $125M | 09/2021 |
Spero Therapeutics investors
| Investors | Security type |
|---|---|
| SR One | Series A |
| Partners Innovation Fund | Series A |
| Atlas Peak Capital | Series A |
| Atlas Venture | Series A |
| GlaxoSmithKline plc | Series A |
| SR One | Series A |
| Partners Innovation Fund | Series A |
| Merck Capital Ventures | Series A |
| Lundbeckfond Ventures | Series A |
| Atlas Venture | Series A |
| The Kraft Group | Series A |
| New England Patriots | Series A |
| GlaxoSmithKline plc | Series B |
| SR One | Series B |
| Partners Innovation Fund | Series B |
| Osage Partners | Series B |
| MRL Ventures Fund LLC | Series B |
| Lundbeckfond Ventures | Series B |
| Atlas Venture | Series B |
| The Kraft Group | Series B |
| SR One | Series C |
| Osage Partners | Series C |
| MRL Ventures Fund LLC | Series C |
| GV | Series C |
| RA Capital Management | Series C |
| Rock Springs Capital | Series C |
| Lundbeckfond Ventures | Series C |
| Atlas Venture | Series C |
| CARB-X | Grant |
| Osage Partners | Post Ipo Equity |
| United States Department of Defense | Grant |
| Pfizer, Inc. | Post Ipo Equity |
| HealthCare Royalty Partners | Post Ipo Debt |
Spero Therapeutics competitors
Spero Therapeutics's top competitor, Anacor Pharmaceutical, earned an annual revenue of $82.4M.
Spero Therapeutics's smallest competitor is Synereca Pharmaceuticals with revenue of $29.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Achaogen | - | $8.7M | 42 | - |
| Cara Therapeutics | - | $7.1M | 84 | - |
| Matinas BioPharma | - | $1.1M | 20 | - |
| Cytokinetics | - | $18.5M | 130 | - |
| Nabriva Therapeutics | - | $12.0M | 175 | - |
| Peptilogics | - | $880,000 | 17 | - |
| Anacor Pharmaceutical | - | $82.4M | 100 | - |
| Iterum Therapeutics plc | - | $1.0M | 48 | - |
| Aclaris Therapeutics | - | $18.7M | 60 | - |
| Synereca Pharmaceuticals | - | $29,000 | 5 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Spero Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Spero Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Spero Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Spero Therapeutics. The data presented on this page does not represent the view of Spero Therapeutics and its employees or that of Zippia.
Spero Therapeutics may also be known as or be related to SPERO THERAPEUTICS, INC., Spero Therapeutics, Spero Therapeutics, Inc. and Spero Therapeutics, LLC.